CA3139161A1 - Inhibitors of fibroblast growth factor receptor kinases - Google Patents

Inhibitors of fibroblast growth factor receptor kinases Download PDF

Info

Publication number
CA3139161A1
CA3139161A1 CA3139161A CA3139161A CA3139161A1 CA 3139161 A1 CA3139161 A1 CA 3139161A1 CA 3139161 A CA3139161 A CA 3139161A CA 3139161 A CA3139161 A CA 3139161A CA 3139161 A1 CA3139161 A1 CA 3139161A1
Authority
CA
Canada
Prior art keywords
optionally substituted
pharmaceutically acceptable
compound
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139161A
Other languages
English (en)
French (fr)
Inventor
Stephen W. Kaldor
John Tyhonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinnate Biopharma Inc
Original Assignee
Kinnate Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinnate Biopharma Inc filed Critical Kinnate Biopharma Inc
Publication of CA3139161A1 publication Critical patent/CA3139161A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3139161A 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases Pending CA3139161A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849534P 2019-05-17 2019-05-17
US62/849,534 2019-05-17
US201962907491P 2019-09-27 2019-09-27
US62/907,491 2019-09-27
PCT/US2020/032939 WO2020236524A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Publications (1)

Publication Number Publication Date
CA3139161A1 true CA3139161A1 (en) 2020-11-26

Family

ID=73458745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139161A Pending CA3139161A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Country Status (7)

Country Link
US (1) US20230174535A1 (enExample)
EP (1) EP3969442A4 (enExample)
JP (1) JP2022533939A (enExample)
CN (1) CN114127051A (enExample)
AU (1) AU2020278566A1 (enExample)
CA (1) CA3139161A1 (enExample)
WO (1) WO2020236524A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
KR20240119095A (ko) * 2021-12-08 2024-08-06 킨네이트 바이오파마 인크. Fgfr 저해제의 고체 상태 형태
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
AU2024301095A1 (en) * 2023-07-26 2026-03-12 Khora Spv 1, Llc Treatment of cancer with a cdk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
GB201503590D0 (en) * 2015-03-03 2015-04-15 Davis Adrian Topical formulation
PT3279202T (pt) * 2015-03-31 2020-08-31 Taiho Pharmaceutical Co Ltd Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
US11221750B2 (en) * 2016-02-12 2022-01-11 Purdue Research Foundation Manipulating 3D virtual objects using hand-held controllers
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US10685111B2 (en) * 2016-10-31 2020-06-16 Crowdstrike, Inc. File-modifying malware detection
US11130761B2 (en) * 2016-12-29 2021-09-28 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors

Also Published As

Publication number Publication date
AU2020278566A1 (en) 2021-12-23
WO2020236524A1 (en) 2020-11-26
EP3969442A4 (en) 2023-08-02
EP3969442A1 (en) 2022-03-23
CN114127051A (zh) 2022-03-01
US20230174535A1 (en) 2023-06-08
JP2022533939A (ja) 2022-07-27

Similar Documents

Publication Publication Date Title
CA3139161A1 (en) Inhibitors of fibroblast growth factor receptor kinases
US11667634B2 (en) Inhibitors of RAF kinases
WO2024178313A1 (en) Kras modulators
US12018033B2 (en) Inhibitors of protein arginine deiminases
WO2023224998A1 (en) Inhibitors of parg
US11780862B2 (en) Inhibitors of MEK kinase
CN113365996A (zh) 咪唑吡啶衍生化合物以及其应用
WO2021247971A1 (en) Inhibitors of fibroblast growth factor receptor kinases
US20240182467A1 (en) Inhibitors of raf kinases
AU2023271807A1 (en) Inhibitors of parg
WO2023107870A1 (en) Inhibitors of fibroblast growth factor receptor kinases
WO2022066580A1 (en) Raf degrading compounds
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
HK40064672A (en) Inhibitors of fibroblast growth factor receptor kinases
WO2025054260A1 (en) Inhibitors of mek kinase
EP4727943A1 (en) Inhibitors of met kinase
WO2025032214A1 (en) Indazole compounds and azaindazole compounds as inhibitors of raf kinases
WO2023187471A1 (en) Heteroaryl derivative compounds, and uses thereof
WO2026060099A1 (en) Selective pi3k inhibitors

Legal Events

Date Code Title Description
U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241114

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105